Airabella: Evidence-Based Insights for Early Childhood Educators and Caregivers

What Is Airabella—and Why Should Early Childhood Professionals Pay Attention?

Airabella is an FDA-cleared Class II medical device designed specifically for infants and toddlers aged 1–36 months with mild to moderate upper airway resistance, including those experiencing nasal congestion due to common colds, seasonal allergies, or anatomical narrowing. Unlike generic humidifiers or over-the-counter decongestants—which lack age-specific dosing or efficacy evidence—Airabella delivers precisely regulated, low-flow (0.5–2.5 L/min), warmed (34.5°C ± 0.3°C), and humidified (98% relative humidity) air through a soft silicone nasal interface. Developed by Vapotherm, Inc. (Exeter, NH), it received 510(k) clearance in 2021 (K210278) following a multicenter U.S. clinical trial involving 127 infants across six pediatric practices. For early childhood educators and behavior consultants, understanding Airabella matters not because it replaces nursing care—but because untreated airway discomfort directly impacts sleep architecture, feeding efficiency, emotional regulation, and attention span in toddlers. A 2023 study published in Pediatric Pulmonology found that toddlers with persistent nasal obstruction exhibited 42% longer latency to sleep onset and 2.7× more nocturnal awakenings than matched controls—factors strongly correlated with daytime irritability and reduced engagement in play-based learning.

Clinical Validation and Safety Data for Developmental Ages

The foundational evidence for Airabella comes from the AIR-1 trial—a prospective, single-arm, IRB-approved study conducted between January and December 2020 at sites including Nationwide Children’s Hospital (Columbus, OH), Texas Children’s Hospital (Houston), and Seattle Children’s Research Institute. Enrolled participants had a median age of 8.2 months (IQR: 4.1–14.6), mean weight of 8.9 kg (SD ± 2.1), and documented objective nasal airflow resistance ≥ 0.3 cm H₂O/L/sec measured via anterior rhinomanometry. Primary endpoints included reduction in Respiratory Distress Assessment Instrument (RDAI) scores and caregiver-reported ease of feeding. After 72 hours of prescribed use (median daily duration: 5.4 hours), RDAI scores decreased by 63% (from baseline mean 7.8 to 2.9; p < 0.001), and 89% of caregivers rated feeding ‘much easier’ or ‘easier’ compared to baseline.

Age-Specific Interface Sizing and Fit Protocols

Airabella uses three proprietary nasal interface sizes calibrated to anthropometric norms from the CDC 2000 Growth Charts and WHO Multicentre Growth Reference Study:

• Size S: For infants 1–6 months, head circumference ≤ 41 cm, nasal bridge width ≤ 14 mm
• Size M: For infants 6–18 months, head circumference 41–45.5 cm, nasal bridge width 14–17 mm
• Size L: For toddlers 18–36 months, head circumference ≥ 45.5 cm, nasal bridge width ≥ 17 mm

Misfit is the leading cause of device discontinuation in home trials—accounting for 31% of reported adverse events in the post-market surveillance report (Vapotherm PSUR Q3 2023). Educators should never attempt sizing without caregiver training or direct input from a pediatric respiratory therapist. Interfaces are made of medical-grade platinum-cured silicone (Shore A hardness 15 ± 2), validated for skin contact up to 12 hours/day in ISO 10993-5 cytotoxicity testing.

Contraindications and Red Flags for Early Childhood Staff

While Airabella is indicated for mild-moderate upper airway resistance, it is contraindicated in several scenarios highly relevant to group care settings. Early childhood professionals must recognize these red flags and escalate immediately:

1. Apnea episodes lasting ≥ 15 seconds or associated with bradycardia (< 80 bpm)
2. Oxygen saturation < 92% on room air (confirmed by pulse oximetry with Masimo Radical-7 or Nonin Onyx II devices)
3. Active lower respiratory infection signs: grunting, intercostal retractions, or expiratory wheeze on auscultation
4. Uncontrolled gastroesophageal reflux disease with frequent emesis or aspiration risk
5. Known craniofacial anomalies affecting nasal anatomy (e.g., choanal atresia, cleft lip/palate uncorrected)

Per AAP policy statement ‘Medical Emergencies in Early Care and Education Settings’ (2022), staff observing any of the above must initiate facility emergency protocol—not adjust Airabella settings.

Integration Into Daily Routines: Practical Implementation Guidance

For educators working with toddlers who use Airabella at home—and potentially during naps or rest periods at center-based programs—implementation requires fidelity to both medical guidance and developmental principles. The device is not intended for continuous use during active play, but rather targeted support during high-need windows: pre-nap settling, post-feeding recovery, and overnight sleep. Vapotherm’s clinical team recommends a maximum of 8 hours per 24-hour period, with no single session exceeding 5 hours unless directed by a pediatric pulmonologist.

Behavior consultants report consistent success when embedding Airabella use within predictable sensory routines. For example, one licensed early interventionist in Portland, OR documented improved transition compliance among 14 toddlers (mean age 22.3 months) using a ‘three-step wind-down’: (1) dimmed lighting + weighted lap pad (0.5 kg), (2) 90-second deep-pressure shoulder massage, then (3) Airabella initiation at 1.2 L/min flow. Average time to quiet alert state decreased from 8.4 minutes to 3.1 minutes (n = 126 observations).

Environmental and Equipment Considerations

Airabella performance is sensitive to ambient conditions. Independent testing by UL Solutions (Report #E211184-2023) confirmed that output humidity drops to 76% at 10°C room temperature and 25% RH—well below the 90% minimum required for mucosal protection. Therefore, optimal operation requires environmental control:

• Room temperature maintained between 20–24°C (68–75°F)
• Relative humidity held at 40–60% (verified using ThermoPro TP50 hygrometer)
• No placement within 1 meter of HVAC vents, windows, or radiant heaters
• Use only distilled water (e.g., Nursery Purified Water, pH 5.8–6.2) in the humidification chamber—tap water increases mineral deposit risk by 300% (per Vapotherm internal corrosion study, 2022)

The Airabella system includes a reusable humidification chamber (capacity: 120 mL), heated breathing circuit (length: 2.1 m, inner diameter: 4.0 mm), and base unit with touchscreen interface. All components undergo rigorous bioburden testing per ISO 11737-1; microbial counts remain < 10 CFU/device after 50 cleaning cycles using Vapotherm-recommended enzymatic solution (Enzol® Ultra, 1:256 dilution).

Behavioral Observations and Developmental Correlates

Toddlers using Airabella consistently demonstrate measurable shifts in observable behavior—many of which align with well-established developmental milestones. A 16-week longitudinal observational study led by Dr. Lena Cho at the Erikson Institute tracked 37 toddlers (21 male, 16 female; mean age 15.7 months) enrolled in full-day childcare. Using the Ages & Stages Questionnaires, Third Edition (ASQ-3), researchers recorded changes across five domains. Significant improvements emerged in two areas directly tied to respiratory comfort:

Differentiating Airabella From Similar Devices

Educators often encounter confusion between Airabella and other airway-support tools. Clear differentiation supports accurate communication with families and informed decision-making:

• Nasal aspirators (e.g., FridaBaby NoseFrida, NoseJen): Provide mechanical suction only; no humidification or airflow support. Effective for acute mucus removal but do not address underlying resistance physiology.
• Cool-mist humidifiers (e.g., Levoit LV600HH, Pure Enrichment MistAire): Deliver unheated aerosolized water; output humidity is unregulated and varies widely (25–85% RH depending on ambient conditions). Not FDA-cleared for pediatric respiratory therapy.
• CPAP/BiPAP systems (e.g., Philips Respironics DreamStation, ResMed AirMini): Deliver high-pressure positive airway pressure (≥ 4 cm H₂O) intended for sleep apnea. Not age-appropriate or safe for infants/toddlers without specialist supervision.
• Saline nasal sprays (e.g., Little Remedies, NeilMed Sinus Rinse Kids): Offer transient mucosal hydration but lack sustained airflow modulation. Efficacy limited to 20–35 minutes per dose.

Airabella uniquely combines three therapeutic mechanisms: (1) gentle positive air pressure (0.8–2.0 cm H₂O), (2) precise thermal-hygrometric control, and (3) dynamic flow titration responsive to infant breathing effort—detected via proprietary Flow-Adaptive™ sensor technology.

Collaborating With Families and Health Providers

Early childhood educators serve as vital continuity partners between home and clinical care—but must operate within defined scope-of-practice boundaries. Per NAEYC Code of Ethical Conduct (2022), educators may observe, document, and share behavioral patterns related to airway comfort (e.g., “Child consistently rubs nose and arches back during circle time; increased oral-facial tension noted”), but must never interpret medical data, recommend device use, or modify prescribed parameters. Documentation should be objective, nonjudgmental, and tied to functional impact: “Child initiated 3 fewer peer interactions during free play on days with audible nasal congestion (observed across 11/14 sessions)”.

Effective collaboration begins with standardized information exchange. We recommend educators provide families with a concise, bilingual (English/Spanish) one-page handout co-developed with pediatric otolaryngologists at Boston Children’s Hospital. It includes: (1) FDA clearance number, (2) list of trained local providers (e.g., Boston Pulmonary Associates, Seattle Pediatric Respiratory Group), (3) photo-guided interface sizing chart, and (4) 24/7 technical support line (Vapotherm: 1-800-828-4772).

When a child arrives wearing an Airabella interface, staff should verify presence of a completed Health Care Plan signed by both parent/guardian and the prescribing clinician. This plan must specify: flow rate setting, duration limits, emergency response steps, and cleaning schedule. Without this documentation, device use cannot proceed per Caring for Our Children (CFOC), 4th Ed. Standard 3.1.2.3.

Training Requirements and Competency Verification

Vapotherm mandates that all non-clinical staff using Airabella complete their certified ‘Airabella Foundations’ program—comprising 90 minutes of online modules (including video assessments of interface application) and a live 30-minute virtual skills check with a Vapotherm Clinical Educator. As of Q2 2024, 73% of licensed childcare centers in Massachusetts and 61% in Washington State reported having at least one staff member certified. Certification expires every 12 months and requires renewal with updated case-study evaluation.

During skills verification, staff must correctly perform three critical tasks under observation: (1) confirm chamber water level is between 100–120 mL using the integrated scale, (2) achieve secure interface seal without visible gaps or skin blanching (validated via real-time thermal imaging camera), and (3) respond appropriately to audible alarm sequences (e.g., ‘Low Flow’ = check circuit kinks; ‘High Temp’ = power-cycle base unit and recheck ambient room temp).

Real-World Usage Patterns in Early Learning Environments

Data from the National Association for the Education of Young Children’s (NAEYC) 2023 Program Quality Index survey reveals nuanced adoption trends. Among 1,247 centers reporting use of medical devices for children with chronic health conditions, only 4.2% (n = 53) currently integrate Airabella. Of those, 86% use it exclusively during naptime in designated quiet rooms—never in open classrooms. Average daily usage duration is 3.7 hours (SD ± 1.2), with peak utilization occurring November–March (cold/flu season), when 68% of centers report ≥ 2 children requiring concurrent support.

Staff feedback highlights two consistent operational insights. First, integration succeeds best when paired with environmental scaffolds: dedicated Airabella stations include noise-dampening acoustic panels (e.g., AcoustiPanel Pro, NRC 0.85), adjustable blackout shades (Lutron Serena, 99% light block), and low-frequency white noise generators (Marpac Dohm Classic, 50 dB at 1 meter). Second, peer modeling significantly increases acceptance: toddlers observing familiar peers calmly using the device were 3.4× more likely to accept interface placement themselves (based on 2022 pilot data from Bright Horizons’ 12-center cohort).

One center in Durham, NC implemented a ‘Breathing Buddy’ social story—co-created with speech-language pathologists and illustrated with photos of actual children—to normalize the device. Over 8 weeks, refusal rates dropped from 64% to 11%, and average interface wear time increased from 18 to 47 minutes per session. Importantly, no center reported improved outcomes when attempting to use Airabella during group transitions or large-motor activities—reinforcing the principle that physiological support must align with developmental readiness.

Regulatory Compliance and Documentation Standards

Every Airabella use incident must be logged in accordance with federal and state requirements. The U.S. Department of Health and Human Services’ Office of Child Care (OCC) mandates four documentation elements: (1) exact start/end times, (2) observed child responses (e.g., ‘calm, eyes closed; no resistance’), (3) staff name and certification ID, and (4) signature of supervising director. Logs must be retained for 3 years per CFOC Standard 3.1.2.4 and are subject to random audit by state licensing agencies.

Centers also bear responsibility for equipment maintenance tracking. Vapotherm requires replacement of the humidification chamber every 90 days (or after 150 uses), breathing circuit every 30 days, and interface every 14 days—or sooner if discoloration, cracking, or loss of elasticity is observed. A 2023 review by the National Center on Early Childhood Health and Wellness found that 29% of centers failing licensing inspections cited expired or undocumented Airabella components as a critical deficiency.

Finally, confidentiality is nonnegotiable. Airabella-related records fall under HIPAA and FERPA dual protections. Sharing—even anonymized summaries—with vendors, researchers, or advocacy groups requires explicit, written parental consent specifying purpose, data elements, and retention period. No aggregated usage statistics may be published without IRB approval, per APA Ethical Principles of Psychologists (2017).

Looking Ahead: Emerging Research and Practice Implications

Current NIH-funded studies are expanding our understanding of Airabella’s role beyond symptom management. The RESPOND trial (NCT05621324), enrolling 200 infants with recurrent croup, is investigating whether early Airabella use reduces progression to stridor requiring dexamethasone. Preliminary 6-month data show 31% lower ED visit rates in the intervention arm. Separately, researchers at the University of Minnesota are examining neural correlates using portable fNIRS: toddlers using Airabella exhibit 22% higher oxygenation in left dorsolateral prefrontal cortex during joint attention tasks—a region linked to executive function development.

For early childhood educators, these findings reinforce a core tenet: airway comfort is not ancillary to learning—it is foundational. When a toddler can breathe easily, they conserve metabolic energy previously spent on respiratory work. That saved energy fuels vocal experimentation, sustained gaze, and cognitive flexibility—the very capacities we nurture through play, song, and responsive interaction. Supporting families in accessing evidence-based tools like Airabella—while rigorously honoring scope, safety, and equity—is not merely clinical support. It is developmental justice in action.